119-HR-8205 DC Insider Whip Count Analysis
119 · HR 8205 Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
H.R. 8205 cleared House Energy & Commerce 46–0 and has broad, organized outside backing; with GOP leadership managing the floor and HELP Chair Cassidy receptive, path to enactment before the Sept. 30, 2026 sunset is strong barring a late Senate UC hold. [1]House Energy & Commerce Committee — E&C Advances 16 Bills to Full House (May 21…
Where the bill stands
H.R. 8205 reauthorizes the 2021 ACT for ALS (P.L. 117‑79) through FY2031 and adds targeted oversight/reporting tweaks. The introduced text (Apr. 6, 2026) and committee documents confirm no new mandatory spending; Section 3(c) includes a Sense of Congress encouraging direct appropriations. [2]govinfo (GPO) — Bill text: H.R. 8205 (Introduced)
- Jurisdiction: House Energy & Commerce (E&C) reported the bill, as amended, to the House by a 46–0 roll call on May 21, 2026. [1]House Energy & Commerce Committee — E&C Advances 16 Bills to Full House (May 21…
- Committee record: House committee repository lists H.R. 8205 and an AINS at the May 21 full committee markup. [3]U.S. House Committee Repository — Committee Repository: E&C Full Committee Mark…
- Background precedent: The original ACT for ALS cleared the House 423–3 under suspension and passed the Senate by unanimous consent in December 2021. [4]Library of Congress — Congress.gov: H.R.3537 (117th) ACT for ALS — actions and…
Breakdown: expected support by party/caucus
Expectation is anchored in the unanimous E&C vote, bipartisan sponsorship, prior near‑unanimous floor history, and visible advocacy pressure.
- House Democrats: Strong yes. Quigley is the sponsor; national ALS groups are publicly pushing swift passage; Democrats backed the 2021 law overwhelmingly (423–3 House vote). Expect broad caucus support again. [5]LegiScan — LegiScan: H.R. 8205 sponsors (Quigley; Calvert)
- House Republicans: Broad yes with a small fiscal‑hawk tail risk. The E&C Chair (Guthrie) advanced the bill 46–0; Calvert is lead GOP co‑sponsor. Some conservatives could balk at the Sense‑of‑Congress language on direct appropriations, but the text is authorization‑focused. Net: strong but not unanimous GOP support. [1]House Energy & Commerce Committee — E&C Advances 16 Bills to Full House (May 21…
- Senate Republicans: Favorable. Senate HELP is chaired by Bill Cassidy (R‑LA), whose office has announced his 119th‑Congress chairmanship and lineup; the Senate passed the 2021 bill by UC. Expect leadership to accommodate passage if the House sends a clean bill. [6]U.S. Senate HELP Committee — HELP: Chair Cassidy and Ranking Member Sanders ann…
- Senate Democrats/Independents: Favorable. Ranking Member Bernie Sanders and prior ACT for ALS champions (e.g., Sen. Chris Coons) have a record of supporting ALS policy; the 2021 bill drew unanimous Senate support. [6]U.S. Senate HELP Committee — HELP: Chair Cassidy and Ranking Member Sanders ann…
Key legislators and pivot points
- House leads: Rep. Mike Quigley (D‑IL) sponsor; Rep. Ken Calvert (R‑CA) co‑lead; E&C Chair Brett Guthrie (R‑KY); E&C Ranking Member Frank Pallone, Jr. (D‑NJ). Their engagement signals bipartisan floor votes and smooth manager’s package if needed. [5]LegiScan — LegiScan: H.R. 8205 sponsors (Quigley; Calvert)
- House floor gatekeepers: Speaker Mike Johnson (R‑LA) and Majority Leader Steve Scalise (R‑LA) control scheduling; health reauthorizations like this typically run on Suspension. Their calendars/press reflect operational control of the 119th agenda. [7]Office of the Speaker of the House — Speaker.gov (119th): Press and statements
- Senate leads: HELP Chair Bill Cassidy (R‑LA) and Ranking Member Bernie Sanders (I‑VT) will quarterback committee handling; Majority Leader John Thune (R‑SD) controls UC and floor time. Expect a UC path unless a member asks for roll‑call. [6]U.S. Senate HELP Committee — HELP: Chair Cassidy and Ranking Member Sanders ann…
- Outside pressure: ALS Association and ALS United are mobilized behind reauthorization with a hard deadline of Sept. 30, 2026, to prevent program lapse, increasing bipartisan incentives to clear the bill. [8]PR Newswire / ALS Association — ALS Association backs ACT for ALS Reauthorizati…
Leadership influence and procedure
- House path: Given the 46–0 committee vote and bipartisan leads, best vehicle is a Suspension‑of‑the‑Rules vote on a negotiated House amendment. Suspension needs two‑thirds; Democrats supplied ample margin in 2021. Leadership can drop it into a Monday/Tuesday block when time opens. [1]House Energy & Commerce Committee — E&C Advances 16 Bills to Full House (May 21…
- Senate path: With GOP control, Thune’s office typically packages low‑controversy health items for UC. Any one senator can object and force floor time. Recent cycles saw targeted UC objections on health‑adjacent items (e.g., pediatric priority review voucher extender), a procedural risk to watch here. [9]U.S. Senate — Senate.gov: Majority/Minority Leaders — roles and current leaders…
Interest‑group landscape
- ALS Association formally backing reauthorization and urging swift action. Useful validator quotes for GOP/Dem floor colloquies. [8]PR Newswire / ALS Association — ALS Association backs ACT for ALS Reauthorizati…
- ALS United running action alerts and messaging on the Sept. 30, 2026 expiry if Congress fails to act. [11]ALS United — ALS United: ACT for ALS reauthorization urgency and Sept. 30, 2026…
- ALS TDI and allied research groups framing the program’s impact and the need to extend funding authority, reinforcing bipartisan optics. [12]als.net
- FDA’s ACT for ALS explainer provides neutral statutory context for member briefs and CRS‑style summaries. [13]U.S. Food & Drug Administration — FDA: ACT for ALS public health focus page
Assessment
- House outlook: High likelihood of passage. Unanimous E&C report and bipartisan leads point to an easy two‑thirds on Suspension. [1]House Energy & Commerce Committee — E&C Advances 16 Bills to Full House (May 21…
- Senate outlook: High, with a UC‑hold caveat. HELP Chair support + 2021 UC precedent suggests a quick clear unless a fiscal hawk forces roll‑call. [6]U.S. Senate HELP Committee — HELP: Chair Cassidy and Ranking Member Sanders ann…
- Timing: Optimal window is June–July; fallback is September before the Sept. 30, 2026 sunset flagged by ALS advocates. [11]ALS United — ALS United: ACT for ALS reauthorization urgency and Sept. 30, 2026…
- Bottom line: Likely to be enacted in this work period; confidence: high.
Key numbers
- [1] E&C Advances 16 Bills to Full House (May 21, 2026) House Energy & Commerce Committee
- [2] Bill text: H.R. 8205 (Introduced) govinfo (GPO)
- [3] Committee Repository: E&C Full Committee Markup (May 21, 2026) U.S. House Committee Repository
- [4] Congress.gov: H.R.3537 (117th) ACT for ALS — actions and votes Library of Congress
- [5] LegiScan: H.R. 8205 sponsors (Quigley; Calvert) LegiScan
- [6] HELP: Chair Cassidy and Ranking Member Sanders announce 119th subcommittee assignments U.S. Senate HELP Committee
- [7] Speaker.gov (119th): Press and statements Office of the Speaker of the House
- [8] ALS Association backs ACT for ALS Reauthorization (Apr. 7, 2026) PR Newswire / ALS Association
- [9] Senate.gov: Majority/Minority Leaders — roles and current leaders (119th) U.S. Senate
- [10] senate.gov
- [11] ALS United: ACT for ALS reauthorization urgency and Sept. 30, 2026 deadline ALS United
- [12] als.net
- [13] FDA: ACT for ALS public health focus page U.S. Food & Drug Administration
Discussion